Short answer
Nuvectis Pharma, Inc. (NVCT) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results and corporate update announced for quarter ended September 30, 2026.
Nuvectis Pharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results and corporate update announced for quarter ended September 30, 2026
- Exhibit 99.1 contains the substantive results and management update for investor review
Item EX-99.1 · Exhibit EX-99.1
- Third-quarter 2026 results reflect major pipeline expansion, with China approval for ciprocopan and $140.7M cash extending runway into 2H 2029
- Ciprocopan’s U.S. path remains the key catalyst, with FDA discussions underway and an update expected before year-end
- NXP200 showed 40.0% ORR in high-grade glioma and 42.9% in low-grade glioma, including complete responses
- Net loss widened to $30.1M from $7.5M, primarily reflecting $20.0M upfront licensing and $1.8M NXP900 milestone payments
- Funding included $115.0M follow-on proceeds and $39.5M ATM proceeds, while shares outstanding rose to 35,031,982 from 25,676,798
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Nuvectis Pharma, Inc. 8-K filings
Get the next NVCT 8-K as it lands
Follow NVCT for push alerts, or ask the research agent what this filing means.